Current guidelines for the management of aggressive non-Hodgkin's lymphoma

Drugs
M MartelliF Mandelli

Abstract

The prognosis of aggressive non-Hodgkin's lymphoma (NHL) has improved greatly during recent years with the use of combination chemotherapy. Planning the treatment must take into consideration the patient's age, performance status, histological subtype and disease extent and severity. Recently, a 4-part International Prognostic Index (IPI), based on 5 prognostic factors, has permitted the allocation of patients with NHL in 2 well defined prognostic groups: good prognosis (low and low-intermediate risk) and poor prognosis (intermediate-high and high risk). Conventional chemotherapy with CHOP (a chemotherapeutic regimen consisting of a combination of cyclophosphamide, doxorubicin, vincristine and prednisone) or other equivalent third-generation regimens may be considered the standard treatment for the good prognosis group. In the poor prognosis group the probability of long term survival is less than 40% with conventional chemotherapy. Therefore, an early intensification with high dose therapy following peripheral stem cell transplantation (PSCT) should be considered in the setting of randomised trials. Localised stage disease, defined as stages I-IE and II-IIE without adverse prognostic factors, has a very good prognosis with a l...Continue Reading

Citations

Apr 30, 1999·Leukemia & Lymphoma·F P PetersH C Schouten
Sep 24, 1999·Leukemia & Lymphoma·F B Hagemeister
Oct 18, 2008·Expert Review of Anticancer Therapy·Vicki A Morrison
May 23, 1998·Blood Reviews·S A Johnson, D S Richardson
May 23, 2003·The Korean Journal of Internal Medicine·Kil Chan Oh, Dae Young Zang
Sep 12, 2013·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Marieke H VerhappenJohn M M Raemaekers
Jun 13, 2002·Cancer Control : Journal of the Moffitt Cancer Center·Elizabeth ChrischillesWilliam B Carter
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A FossåM R Nowrousian

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.